This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Analía Bortolozzi Biassoni
Researcher, Neuroscience & Experimental Ther at Institute of Biomedical Research of Bar

Profile

Analia Bortolozzi is a senior scientist at the Spanish National Research Council (CSIC) and leads group CB/07/09/0034 of the Center for Biomedical Research in Mental Health Network (CIBERSAM). She received her PhD in Neuropharmacology at the University of Rosario, Argentina (2000) and did her postdoctoral training at the Institute for Biomedical Research in Barcelona, Spain (2000-04). In 2004-09, she received the Ramon y Cajal award and the I3 award for Research Excellence. Broadly terms, her research focuses on brain circuits and synaptic processes involved in the pathophysiology and treatment of depression and Parkinson's disease. She addresses the development of modified oligonucleotides to modulate RNA expression/function in midbrain monoaminergic neurons of mice and monkeys, which has led to the invention of several patents. She has received numerous international grants and awards, including the Brain and Behavior Research Foundation, the Michael J Fox Foundation, and the Pfizer Foundation Award for Basic Research. She is an active collaborator to miCure Therapeutics, which grew out of the Weizmann Institute. Bortolozzi is an associate editor of J Psychiatry and Mental Health, and serves on various boards and review panels, including the Spanish State Research Agency (AEI) and the French National Research Agency (ANR).

Agenda Sessions

  • Conjugated ASO/siRNAs as Therapeutic Tools for Brain Disorders Associated with Derangements of Midbrain Monoamine Systems

    2:00pm